# Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ARCT
## Company Profile
- Ticker: ARCT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 15.56 USD
- Market cap: 217436477.85000002 USD
- Last updated: 2026-09-03
## Business Overview
Arcturus Therapeutics is an RNA medicines company focused on mRNA and self-amplifying RNA technologies. Its story is built around platform science that aims to produce vaccines and therapeutics across multiple disease areas.
## Why The Stock Is Moving

As of Sep 3, 2026, ARCT closed down 7.05% at $15.56. No new same-company headline was identified in the current news window.

## Geographic Base

Arcturus is headquartered in the United States and listed on NASDAQ. It sits in platform biotechnology with a strong RNA-technology identity.

## Business Model

The company depends on platform validation, clinical progress, and the ability to convert RNA science into durable product revenue. Investors watch vaccine or therapeutic data, partnerships, and manufacturing capability.

## Landscape Position

Arcturus occupies a platform-RNA niche within biotech. It is sensitive to whether self-amplifying RNA can create differentiated therapeutic value beyond the first wave of products.

## Future Catalysts

- Arcturus’s catalysts are mRNA-platform updates, vaccine and therapeutic development, and any partnership or clinical step that keeps the platform credible. The company still needs human proof.

## Recent News
- 2020-09-08 12:30 EST — [Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences](https://biopharmsignal.com/news/ARCT/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-67374ee8) — Source: Arcturus Therapeutics Holdings Inc.
- 2020-09-04 14:31 EST — [Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate](https://biopharmsignal.com/news/ARCT/arcturus-therapeutics-announces-preclinical-publication-of-its-covid-19-vaccine--8539d8a1) — Source: Arcturus Therapeutics Holdings Inc.
- 2020-08-18 13:00 EST — [Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health](https://biopharmsignal.com/news/ARCT/arcturus-therapeutics-executes-definitive-supply-agreement-with-the-israeli-mini-de7a43aa) — Source: Arcturus Therapeutics Holdings Inc.
- 2020-08-11 12:00 EST — [Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study](https://biopharmsignal.com/news/ARCT/arcturus-therapeutics-announces-that-it-has-initiated-dosing-of-its-covid-19-sta-09be1816) — Source: Arcturus Therapeutics Holdings Inc.
- 2020-08-10 20:01 EST — [Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and  Provides a Corporate Update](https://biopharmsignal.com/news/ARCT/arcturus-therapeutics-announces-second-quarter-2020-financial-results-and-provid-e3a8200b) — Source: Arcturus Therapeutics Holdings Inc.